Literature DB >> 20685571

Glucagon-like peptide 1--a cardiologic dimension.

Marek Treiman1, Mikkel Elvekjaer, Thomas Engstrøm, Jan Skov Jensen.   

Abstract

Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20685571     DOI： 10.1016/j.tcm.2010.02.012

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN： 1050-1738            Impact factor:   6.677


  7 in total

1.  Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects.

Authors:  Martin Haluzík; Miloš Mráz; Štěpán Svačina
Journal:  Drug Saf       Date:  2014-12       Impact factor: 5.606

2.  Epac2-dependent mobilization of intracellular Ca²+ by glucagon-like peptide-1 receptor agonist exendin-4 is disrupted in β-cells of phospholipase C-ε knockout mice.

Authors:  Igor Dzhura; Oleg G Chepurny; Grant G Kelley; Colin A Leech; Michael W Roe; Elvira Dzhura; Parisa Afshari; Sundeep Malik; Michael J Rindler; Xin Xu; Youming Lu; Alan V Smrcka; George G Holz
Journal:  J Physiol       Date:  2010-11-01       Impact factor: 5.182

Review 3.  The shifting paradigm in the treatment of type 2 diabetes mellitus-A cardiologist's perspective.

Authors:  Saeeda Fatima; Ayesha Jameel; Fnu Ayesha; Dhananjai J Menzies
Journal:  Clin Cardiol       Date:  2017-08-25       Impact factor: 2.882

Review 4.  Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.

Authors:  James H Flory; Jenny K Ukena; James S Floyd
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

5.  Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury.

Authors:  Masayoshi Oikawa; Meiping Wu; Soyeon Lim; Walter E Knight; Clint L Miller; Yujun Cai; Yan Lu; Burns C Blaxall; Yasuchika Takeishi; Jun-ichi Abe; Chen Yan
Journal:  J Mol Cell Cardiol       Date:  2013-08-27       Impact factor: 5.000

Review 6.  The cardiovascular safety of incretin-based therapies: a review of the evidence.

Authors:  John R Petrie
Journal:  Cardiovasc Diabetol       Date:  2013-09-06       Impact factor: 9.951

Review 7.  Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery.

Authors:  Derek J Hausenloy; Jose A Barrabes; Hans Erik Bøtker; Sean M Davidson; Fabio Di Lisa; James Downey; Thomas Engstrom; Péter Ferdinandy; Hector A Carbrera-Fuentes; Gerd Heusch; Borja Ibanez; Efstathios K Iliodromitis; Javier Inserte; Robert Jennings; Neena Kalia; Rajesh Kharbanda; Sandrine Lecour; Michael Marber; Tetsuji Miura; Michel Ovize; Miguel A Perez-Pinzon; Hans Michael Piper; Karin Przyklenk; Michael Rahbek Schmidt; Andrew Redington; Marisol Ruiz-Meana; Gemma Vilahur; Jakob Vinten-Johansen; Derek M Yellon; David Garcia-Dorado
Journal:  Basic Res Cardiol       Date:  2016-10-20       Impact factor: 17.165
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.